An Open-Label, Phase I/II, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumours or Non-Hodgkin's Lymphoma and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
This is an open-label, multicentre, Phase I/II study to assess the safety, tolerability, and
pharmacokinetics of GDC-0032. The Phase I portion will be divided into two stages. During
Stage 1, GDC-0032 will be administered every day orally (PO) and at escalating doses in
participants with locally advanced or metastatic solid tumours. During Stage 2, GDC-0032 will
be administered alone or as combination therapy within indication-specific cohorts. In Phase
II of the study, the efficacy and safety of the combination GDC-0032 and fulvestrant will be
evaluated in post-menopausal female participants with locally advanced or metastatic human
epidermal growth factor receptor 2 (HER2)-negative, hormone receptor-positive breast cancer.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society